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Abstract
Purpose: To report the long-term oncologic outcomes and survival estimates associated with minimally in-
vasive partial nephrectomy (MIPN) and to determine factors associated with those outcomes and survival
estimates.
Patients and Methods: A single-institution, retrospective review was performed on all patients undergoing
MIPN for renal-cell carcinoma between 1998 and 2011 with minimum 1-year follow-up. Bivariate and mul-
tivariate analyses were performed to assess associations between demographic, perioperative, and tumor factors
with recurrence and survival. Survival was estimated using the Kaplan-Meier method.
Results: Of 417 patients undergoing MIPN, median overall and oncologic follow-up were 3.3 and 2.9 years,
respectively. The mean patient age was 63 years (standard deviation [SD]– 13.4). The mean tumor size was
2.9 cm (SD– 1.48). Only 6.7% of patients had a pathologic stage T2 or greater. There was only one cancer-
related death. Estimates for overall survival at 2, 5, and 10 years were 95.6%, 89.1%, and 70.7%, respectively.
Estimates for recurrence-free survival (any recurrence) at 2, 5, and 10 years were 98.2%, 93.5%, and 88.3%,
respectively. On multivariate analysis, only tumor stage was associated with recurrence, and only patient age
and American Society of Anesthesiologists score were associated with overall survival. Technical aspects of the
procedure, such as positive margins or use of enucleation, did not influence recurrence or survival.
Conclusions: Cancer recurrence after MIPN, in a cohort of patients with mostly pT1 tumors, is rare. Recurrence
and overall survival are associated with nonmodifiable factors rather than technical ones.
Introduction
For small renal parenchymal tumors, partial ne-phrectomy (PN) has become a standard of care even in
the presence of a normal contralateral kidney. Underused a
decade ago,1 more recent data suggest increasing applica-
tion of partial as opposed to radical nephrectomy.2,3 Al-
though open surgical PN is the gold standard approach to PN,
particularly for complex tumors,4,5 minimally invasive PN
(MIPN) appears to have comparable short-term functional
and oncologic outcomes.6,7 As such, MIPN is also increasing
in utilization.8 This has occurred without widespread con-
firmation of long-term oncologic efficacy, with only Lane
and associates9–11 reporting oncologic outcomes of MIPN
after 5, 7, and 10 years.
Consequently, the aim of this study is to identify factors
associated with long-term overall and cancer-related sur-
vival after MIPN, with the hope of informing preoperative
patient selection and intraoperative decision making, and to
potentially direct future research on the oncologic efficacy of
MIPN.
Patients and Methods
All patients undergoing MIPN (includes standard, hand-
assisted, and robotic-assisted laparoscopy) at our institution
between November 1998 and September 2011 were included
in our Institutional Review Board approved and prospec-
tively maintained database. A total of 480 patients underwent
MIPN for pathologically confirmed renal-cell carcinoma;
those with benign pathology were excluded from this anal-
ysis. Of these patients, a minimum 1-year follow-up was
available in 417 patients. Long-term oncologic data were
obtained and analyzed retrospectively from medical records,
radiographic reports, tumor and death registries, and contact
with patients, their families, and referring physicians’ offices.
In patients with bilateral disease managed with staged pro-
cedures (n = 3), only the first operation was included. Patients
with preexisting metastatic disease were excluded from the
study.
Our follow-up surveillance protocol comprised regular
history and physical examinations together with laboratory
testing, chest radiography, and computed tomography (CT)
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or magnetic resonance imaging (MRI) of the abdomen,
generally following the recommendations of Lam and col-
leagues.12 For patients who underwent follow-up at another
institution, reports from the referring physician were obtained
and entered into our computerized database. All patients were
accounted for in calculating overall survival (n= 417). In de-
termining oncologic follow-up, chest radiography or cross-
sectional imaging was required. Only four patients lacked
documentation of the imaging necessary for oncologic follow-
up to estimate recurrence-free survival (n= 413), which in-
cluded recurrence locally (anywhere in the ipsilateral kidney),
regionally, or systemically. Cause of death was ascertained
using a combination of sources: Physician note, hospital re-
cords, and the Social Security Death Index.
The surgical approach (i.e., standard laparoscopic partial
nephrectomy [SLPN], hand-assisted laparoscopic partial
nephrectomy [HALPN] and robot-assisted laparoscopic
partial nephrectomy [RALPN] ), use of hilar clamping, and
the performance of enucleation vs sharp excision of tumor
were determined based un tumor characteristics and surgeon
preference.
The dependent variables for statistical analysis were
overall survival, cancer-specific survival, and recurrence-free
survival. Bivariate assessments were made with the log rank
test, using the following independent variables: Patient age,
American Society of Anesthesiologists (ASA) score, and
preoperative estimated glomerular filtration rate (eGFR),
(calculated using the Modification of Diet in Renal Disease
equation13); tumor stage, grade, and size; surgical approach;
enucleation vs sharp excision; ischemia time; and positive
margin. We did not assess tumor cell type because of the small
number and heterogeneity of nonclear cell types. We then fit
Cox proportional hazards models after backward selection for
the most parsimonious model to evaluate for association using
those independent variables significant on bivariate analysis.
Associations are shown as hazard ratios with 95% confidence
intervals (CIs). Statistical analyses were performed using SAS
9.2 software (SAS Institute, Cary, NC).
Results
Among the 417 patients, the mean patient age was 63 years
(standard deviation [SD] – 13.4), 62% were ASA 1 or 2, and
the mean pre-operative eGFRwas 79 (SD – 22.4). Among the
MIPN, there were 212 SLPN, 91 HALPN, and 114 RALPN.
The mean tumor size was 2.9 cm (SD– 1.48). Cell-types in-
cluded clear-cell in 284 (68%), papillary type 1 in 83 (20%),
chromophobe in 28 (6.7%), papillary type 2 in 4 (1.0%), and
other or mixed in 18 (4.3%). The tumor grade was 1 or 2 in
271 (65%) patients, and 3 or 4 in the remainder. Most tumors
were stage pT1a (329, 79%) or pT1b (59, 14%), with only 28
(6.7%) being tumor stage pT2 or greater (data missing in one
patient). Of the procedures, 15% involved tumor enucleation
and 85% were performed with sharp excision. The mean is-
chemia time was 21 minutes (SD – 14.2). The final surgical
margin was positive for tumor in 23 (5.5%) patients.
The median overall follow-up was 3.3 years (interquartile
range [IQR] 2.0–6.0 years), including 120, 70, and 15 pa-
tients with follow-up more than 5, 7, and 10 years, respec-
tively. There were 44 deaths overall. Only one patient died of
renal cancer. Median oncologic follow-up was 2.9 years (IQR
1.5–4.8 years). There were 17 recurrences (4.1%), including
7 (1.7%) in the ipsilateral kidney, 2 in the contralateral kid-
ney, 3 in the lung, and 5 at other sites. Estimates for overall
survival at 2, 5, and 10 years (95% CI) were 95.6% (93.0,
97.2), 89.1% (84.5, 92.4), and 70.7% (56.7, 80.9), respec-
tively. Because there was only one death from renal cancer,
we did not calculate cancer-specific survival. Estimates for
recurrence-free survival (any recurrence) at 2, 5, and 10 years
(95% CI) were 98.2% (96.1, 99.2), 93.5% (88.8, 96.3), and
88.3% (79.6, 93.5), respectively.
Bivariate analyses are summarized in Tables 1A and 1B.
Older patient age was associated with tumor recurrence, as
were greater tumor stage, grade, and size, as well as the oc-
currence of a positive surgical margin. Notably, of the 23
patients with positive margin of resection, only 3 had any
form of recurrence with 2 recurrences (8.7%) specifically
Table 1A. Bivariate Analysis of Overall and Recurrence Free Survival
No. with
overall death
No. with
recurrence
Variable Strata n = 44 P-value n= 17 P-value
Tumor stage* T1a 34 0.12 7 < 0.0001
T1b 5 4
T2 or T3a 5 6
Tumor grade 1 or 2 28 0.42 7 0.03
3 or 4 16 10
ASA 1 or 2 15 9 0.21
3 or 4 29 < 0.0001 8
Approach RALPN 3 0.34 2 0.81
HALPN 19 4
SLPN 22 11
Enucleation No 38 0.55 14 0.21
Yes 6 3
Positive margin No 42 0.97 14 0.047
Yes 2 3
*Missing 1 patient.
ASA=American Society of Anesthesiologists; RALPN = robot-assisted laparoscopic partial nephrectomy; HALPN= hand-assisted
laparoscopic partial nephrectomy; SLPN = standard laparoscopic partial nephrectomy.
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located in the ipsilateral kidney. From a different perspective,
of the seven patients with recurrence in the ipsilateral kidney,
two (29%) were associated with positive margins. In the three
patients with positive surgical margins and recurrence, the
median time to presentation of recurrence was 30 months. In
the 20 patients with positive surgical margins but no recur-
rence, the median oncologic follow-up was 31 months.
Overall survival was reduced in older patients and those with
greater ASA score and lower preoperative eGFR. We also
tested the association of tumor recurrence with overall sur-
vival, and there was none (P = 0.92, data not shown).
Figure 1 depicts the Kaplan-Meier survival curves for
recurrence-free survival, stratified by tumor stage. Figure 2
depicts the Kaplan-Meier survival curves for overall survival,
with Figure 2A stratified by age and Figure 2B stratified by
ASA score. Of note, the survival estimate for overall survival
reached 0% in the subcohort with ASA score 3 or 4 just
beyond 12 years.
Results from the multivariate analyses are presented in
Table 2. For recurrence, only tumor stage remained associ-
ated (P < 0.0001). The hazard ratios (relative to stage pT1a)
were 4.81 (95% CI, 1.37–16.97) for stage pT1b and 19.46
(95% CI, 5.87–64.59) for stage pT2 or greater. Of the three
factors associated with overall survival on bivariate analysis
(patient age, ASA score, and preoperative eGFR), the last
factor lost significance on multivariate analysis. The hazard
ratio for age (P< 0.0002) was 1.05 (95% CI, 1.02–1.08), with
each additional year being associated with a 5% increase in
the hazard of death. ASA score 3 or 4 (P < 0.0002) was as-
sociated with a hazard ratio of 3.53 (95% CI, 1.81–6.85),
relative to ASA score 1 or 2.
Discussion
The management of small renal masses has evolved over
the last decade from open surgical PN designed for maxi-
mum cancer control to include MIPN focused on the com-
bined goals of oncologic efficacy, reduction of the duration
and intensity of convalescence, and preservation of renal
function.14 A number of groups have reported their perio-
perative and short-term experiences with MIPN, suggesting
excellent oncologic efficacy, as well as low recurrence
Table 1B. Bivariate Analysis of Overall and Recurrence-Free Survival
Overall survival Recurrence-free survival
Variable (mean – SD) Death No death P-value Recurrence No recurrence P-value
Preoperative eGFR
(mL/min per 1.73m2)
71– 4.0 81 – 1.1 0.04 73– 6.5 80– 1.1 0.41
Age (years) 75– 2.0 62 – 0.7 < 0.0001 72– 2.3 63– 0.7 0.048
Tumor size (cm) 2.9 – 0.2 2.9 – 0.09 0.16 3.9 – 0.5 2.9 – 0.07 0.001
Ischemia time (min) 18– 2.1 21 – 0.7 0.50 22– 4.4 21– 0.7 0.40
SD = standard deviation; eGFR = estimated glomerular filtration rate.
FIG. 1. Kaplan-Meier survival curve
for recurrence-free survival, stratified by
tumor stage.
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rates.15,16 Longer follow-up, however, is needed to confirm
the oncologic efficacy of MIPN.
Some series that report oncologic follow-up in excess of 3
years are limited by the size of their cohorts.17,18 Lane and
associates11 recently reported a series that included 45 pa-
tients with more than 10 years follow-up after MIPN; overall
survival was 78% at 10 years, and metastasis-free survival
was 97%. Using both laparoscopic and open surgical cohorts,
these authors identified several independent predictors of
overall survival and recurrence in the long term: Older age,
larger tumor size, absolute indication, and Charlson co-
morbidity index. Because ASA score and Charlson
FIG. 2A. Kaplan-Meier survival curve
for overall survival, stratified by age.
FIG. 2B. Kaplan-Meier survival curve
for overall survival, stratified by Ameri-
can Society of Anesthesiologists score.
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comorbidity index appear to predict mortality equally
well,19,20 these findings are similar to ours with regard to
overall survival. With regard to tumor recurrence, Lane and
associates11 found that surgery type was not associated with
oncologic outcome, again similar to our finding that no
technical aspects influenced recurrence-free survival.
Finally, our finding on multivariate analysis that positive
surgical margins were not associated with tumor recurrence is
consistent with a growing body of evidence.21–23 There are
several possible explanations for the observation that positive
surgical margins on pathologic examination of the resected
tumor do not result in recurrence in many cases, including:
Intraoperative fulguration of the tumor bed, ischemic damage
to residual tumor from hemostatic sutures, retraction of normal
parenchyma away from the tumor during tissue processing,
and/or the appearance of a positive margin when the resection
was adjacent to the tumor’s pseudocapsule and in fact there is
no tumor left in the patient. Alternatively, it may be that the
duration needed for positive margins to produce a clinically
noticeable tumor has not yet been achieved in most series.
In our cohort, characterized by relatively young and
healthy patients with good renal function and small, low-risk
tumors, the risks of recurrence and death were low, with
estimated 88.3% recurrence-free survival and 70.7% overall
survival at 10 years. There was only one cancer-related death.
Of the 17 patients with recurrence, only 4 (3 with pulmonary
metastases and 1with abdominal lymph nodemetastases) had
recurrence beyond the ipsilateral or contralateral kidney,
adrenal gland, or a resectable solitary metastasis. As such,
oncologic risk factors impacted only recurrence, and not
survival. The excellent oncologic outcomes in our cohort do
suggest great efficacy of MIPN, but they also suggest the
possibility that at least some of these small renal cancers are
being overtreated. In particular, competing causes of mor-
tality are especially important, as illustrated by the finding of
no survival beyond 12 years in patients with ASA score 3 or
4. We, like many other groups, are increasingly using active
surveillance in patients with small renal masses and high
competing risks of mortality.24 The excellent results of MIPN
provide the context in which we should assess active sur-
veillance strategies going forward.
The present study has several limitations including the se-
lection bias for patients with unilateral, low-volume disease,
the changes in surgery and practice patterns over the last de-
cade, the varied learning curves of the different surgeons, er-
rors in retrospective data extraction, and variability of patient
follow-up. Despite these limitations, we think that this evalu-
ation of the long-term outcomes of a large cohort of MIPN
patients is crucial to better understanding this procedure.
Conclusion
To our knowledge, this is the first study in the literature to
examine long-term (‡ 3 years) oncologic outcomes after
three different types of MIPN in a large population with each
patient having at least 1 year of follow-up. Our data confirm
that MIPN, in a cohort of mostly pT1 tumors, is associated
with infrequent tumor recurrence even on long-term follow-
up. Only tumor stage influences recurrence; the technical
aspects of MIPN such as the surgical approach (SLPN,
HALPN, or RALPN) or the method of resecting the tumor
(enucleation or sharp excision) were not associated with re-
currence. With limited impact of these small renal cancers on
mortality, the clinician’s operative decisions should be gui-
ded by the understanding that recurrence-free survival is
influenced by tumor stage and that overall survival is influ-
enced by patients’ age and medical condition.
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Abbreviations Used
ASA¼American Society of Anesthesiologists
CI¼ confidence interval
CT¼ computed tomography
eGFR¼ estimated glomerular filtration rate
HALPN¼ hand-assisted laparoscopic partial
nephrectomy
IQR¼ interquartile range
MIPN¼minimally invasive partial nephrectomy
MRI¼magnetic resonance imaging
PN¼ partial nephrectomy
RALPN¼ robot-assisted laparoscopic partial
nephrectomy
SD¼ standard deviation
SLPN¼ standard laparoscopic partial nephrectomy
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